---
document_datetime: 2026-02-16 10:50:48
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1659552
conversion_datetime: 2026-02-18 17:54:04.35007
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## JEMPERLI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | B.I.a.1 Change in the manufacturer of a | 22/01/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309506                     | starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted   |            |            |             |           |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| PSUR / EMA/PSUR/0000288247            | In view of available data on Stevens- Johnson syndrome from spontaneous reports and in view of a plausible mechanism of action, the PRAC Rapporteur considers that a causal relationship between dostarlimab and Stevens-Johnson syndrome (SJS) is at least a reasonable possibility. The PRAC Rapporteur concluded that the product information of products containing dostarlimab should be amended accordingly.                                                                                                                                 | 11/12/2025 | 10/02/2026 | SmPC and PL | Variation |
| Variation type IA / EMA/VR/0000313767 | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active                                                                                                                                                                                                                                                                                                                                                                                                       | 05/12/2025 |            |             |           |

<div style=\"page-break-after: always\"></div>

|                                                         | substance - B.I.a.4.a Tightening of in- process limits - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |            |            |                        |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IB / EMA/VR/0000305087                   | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                   | 10/11/2025 |            |                        |
| Variation type IB / EMA/VR/0000301588                   | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted                                                                                       | 23/10/2025 |            |                        |
| Marketing Authorisation Transfer - H / EMA/T/0000292052 | transfer of marketing authorisation from GlaxoSmithKline (Ireland) Limited to GlaxoSmithKline Trading Services Limited                                                                                                                                                                                                                    | 01/09/2025 | 15/09/2025 | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000287894                | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                       | 11/08/2025 |            |                        |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000264716   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted                                                                                         | 16/06/2025   |            |                 |                                                                                                                                                                                                     |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000263951   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                                                                                                                       | 06/06/2025   |            |                 |                                                                                                                                                                                                     |
| Variation type II / EMA/VR/0000256521   | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.3 Including | 05/06/2025   | 15/09/2025 | Annex II and PL | The Annex II has been updated to add the new manufacturer responsible for batch release: GlaxoSmithKline Manufacturing S.p.A Strada Provinciale Asolana, 90, 43056 San Polo di Torrile Parma, Italy |

<div style=\"page-break-after: always\"></div>

|                                       | batch control/testing for a biological/immunological product and any of the test methods performed at that site is a biological / immunological / immunochemical method - Accepted                                                  |            |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IB / EMA/VR/0000255440 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                       | 30/04/2025 |
| Variation type IB / EMA/VR/0000248620 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted | 20/02/2025 |